He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.

He describes one patient data from an investigator led study in Europe, and explains how Sana's program is slighly different. The company aims to file an IND this year. Plus, discussing the company's unique delivery mechanism for in vivo CAR-T.

An early pioneer in the space, she describes the current state of AI in life sciences and the progress that Insitro is making.

He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.

Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that acts on targets in the brain.

Najat Khan describes the impact Recursion's work is having, such the surprising PoC of using MEK1/2 inhibition as a target for treating Familial Adenomatous Polyposis (PAP). Plus, she discusses other programs and large-pharma partnerships, and using new tools such as Boltz-2.

He describes the 'best-in-class' profile he believes INHBE can show in the obesity space. Plus the latest on other programs and how Wave is working on a new a new bifunctional modality.

He shares updates on Brepocitinib, IMVT-1402, and the company's LNP lawsuit against Moderna.

He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.

He describes the launch, physician and patient feedback, and responds in his own words to short seller criticism.

He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.

He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.

She discusses the profile of the drug, which is currently in a phase 3 study, and the data Bluejay had previously presented on it. Plus, her advice for other entrepreneurs who might be fielding bids.

She discusses the launch and financial guidance for next year, and highlights obesity and Huntington's programs.

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.

She describes the HOPE-3 data, the regulatory filing, which has already been initiated in part, and what she believes this treatment means for DMD patients.

He discusses programs covering dry eye, ocular pain, AMD, geographic atrophy, and more. Plus, how he using Bausch + Lomb's expertise in the eye and investing in biotech technologies of the future.

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.